Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 110 participants.

Also called NCT04095793

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 110 participants (enrolled count) (from the registry)
Sponsor
Theravance Biopharma (from the registry)
Registry
  • NCT NCT04095793
  • EudraCT 2019-002425-30
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Bulgaria, Canada, Denmark, Estonia, France, Germany, Israel, Italy, New Zealand, Poland, Portugal, Russia, Spain, Ukraine, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT04095793. Allocation not applicable; no masking; primary purpose treatment. Start 2019-09-19 (actual); primary completion 2021-11-12 (actual). Results posted on 2022-11-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
Acronym
OAK
Condition
Symptomatic Neurogenic Orthostatic Hypotension
Intervention (Drug)
ampreloxetine
Lead sponsor
Theravance Biopharma (class: industry)

Record details

Record id
cardio:ct-nct04095793
Content hash
496a96defa1ee30c93d456c37322edf4470805116b9c6048bb54e2dc8dace8dd